Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized dose-finding study of GSK1070806 in moderate-to-severe atopic dermatitis
jRCT2071230084Phase 2Completed
- Sponsor
- GSK
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing GSK1070806 arm with Placebo arm (2 arms). Primary endpoint: Percent change from baseline in Eczema Area and Severity Index (EASI) at Week 16. Started Dec 2023; status: completed.
02
Drugs
aletekitug
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2071230084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071230084.